CliffBio
biologic

Crysvita

burosumab-twza

Loss of exclusivityApril 2030projected — 12-year biologic exclusivity estimate
CompanyKyowa Kirin Co. →View the full company profile on CliffBio

Drug detail

Brand nameCrysvita
Active ingredientburosumab-twza
Strength30MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2018
Marketing statusRx

More from Kyowa Kirin Co.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Crysvita patent cliff — loss of exclusivity April 2030 | CliffBio